Analytical Data
-
基因名
SLC8A1
- Application
-
别名
Na(+)/Ca(2+)-exchange protein 1 Solute carrier family 8 member 1
-
种属
Human
-
表达系统
Yeast
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P32418
-
表达区间
396-627aa
-
分子量
27.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC8A1, also known as the sodium/calcium exchanger 1 (NCX1), is a crucial membrane protein that plays a significant role in cellular calcium homeostasis by facilitating the exchange of sodium and calcium ions across the plasma membrane. Its function is vital in various physiological processes, including cardiac and neuronal excitability, muscle contraction, and intracellular signaling pathways. Dysregulation of SLC8A1 has been implicated in several pathological conditions, such as heart disease, neurological disorders, and hypertension. The study of SLC8A1 recombinant protein has become increasingly important for understanding its molecular mechanisms and potential therapeutic targets. By expressing and purifying SLC8A1 in various heterologous systems, researchers aim to elucidate its structural features, ion binding properties, and transport kinetics. This research has significant implications for the development of drugs that can modulate SLC8A1 activity, offering potential treatment strategies for diseases associated with calcium dysregulation. Overall, the investigation of SLC8A1 recombinant protein not only enhances our fundamental knowledge of ion transport mechanisms but also paves the way for innovative approaches in drug discovery and development.
